Recently, Clariant has been expanding its Clear Lake facility, adding a new production line for pharmaceutical-grade polyethylene glycol (PEG) excipients that complies with Good Manufacturing Practice (GMP) standards. This will significantly increase the supply and reliability of excipients for customers in North America and expand into the Latin American market. This phased expansion is designed to address key industry needs in terms of supply chain security, continuity, and responsiveness, while also reflecting Clariant's long-term strategic commitment to the U.S. pharmaceutical market.
The Clear Lake facility is Clariant's first production base in the United States dedicated to manufacturing pharmaceutical-grade polyethylene glycol (PEG) excipients, marking an important milestone in the company's healthcare growth strategy. By establishing regional production capacity, Clariant is building a more resilient and responsive supply chain infrastructure for pharmaceutical companies in the region.
The upgrade and operation of the Clear Lake facility are designed to meet the pharmaceutical industry's most stringent quality, safety, and regulatory requirements. GMP compliance for excipients ensures that all production processes align with international pharmaceutical excipient standards, providing customers with the documentation, traceability, and quality assurance needed for regulated drug manufacturing. Clariant's pharmaceutical-grade polyethylene glycol (PEG) is registered in relevant pharmacopoeias and has extremely low toxicity, making it suitable for a wide range of applications.
